glp 1 agonists and inflammation Frontiers Nephroprotective effects of GLP-1 receptor
Description
For non-GLP-1 oral options, Qsymia provides the strongest weight loss results among oral alternatives
Accordingly, and in line with currently ongoing trials in HFpEF (ClinicalTrials.gov IDs NCT04916470 and NCT04788511), it may be relevant to consider obesity-related HFpEF as a specific (sub)phenotype, whether coexisting with type 2 diabetes or not
This works because tirzepatide is not simply a stronger version of semaglutide
MEET THE OWNER, ALANE WINCEK
So we rolled up our sleeves and dug into the actual science
